BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Mirum Pharmaceuticals\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Mirum Pharmaceuticals\, Inc.'s dr
 ugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05050136-10898@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:volixibat: Phase 2 readout est. (NCT05050136)
DESCRIPTION:volixibat\, phase 2\, Primary Biliary Cholangitis.\nStudy: A St
 udy to Evaluate Efficacy and Safety of an Investigational Drug Named Volix
 ibat in Patients With Itching Caused by Primary Biliary Cholangitis\nEstim
 ated primary completion: January 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/volixibat#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05050136
URL:https://assetmemo.bio/drug/volixibat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07823127-10897@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20290112
DTEND;VALUE=DATE:20290113
SUMMARY:Livmarli (maralixibat): Phase 2 readout est. (NCT07823127)
DESCRIPTION:Livmarli (maralixibat)\, phase 2.\nStudy: MRX-901: An Open-labe
 l Study to Assess Safety and Tolerability of Maralixibat in Participants W
 ith Intrahepatic Cholestasis of Pregnancy (ICP)\nEstimated primary complet
 ion: 12 January 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /maralixibat#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07823127
URL:https://assetmemo.bio/drug/maralixibat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
